| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
To study the efficacy and safety of Bifidobacterium breve (B.breve) on low birth weight infant in NICU we examined the optimum way of B.breve administration. 10 extended 9 CFU of B.breve dissolved 4ml of distilled water should be ingested at once during stable period. Early administration of B. breve indicated that the microbiota could colonize in the later life of infants.
After B.breve administration, significant increases in the numbers of Bifidobacterium in both the cecum and colon were confirmed during the newborn period. The expression of inflammation-related genes, including glutathione peroxidase 2 was significantly reduced in the colon during the newborn period. On the other hand expression of CXCL13 and IgA production in the colonic mucosa was significantly increased.
|
